You are here
Inhibikase Therapeutics, Inc.
https://www.inhibikase.com
UEI: E5PSKKJUHEW4
# of Employees: 5
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Kinase activation in multiple system atrophy
Amount: $385,888.00Multiple system atrophy (MSA) is an unrelenting neurodegenerative disorder with an uncertain etiology and pathophysiology. MSA is a unique proteinopathy in which alpha-synuclein accumulates preferenti ...
SBIRPhase I2021Department of Health and Human Services National Institutes of Health -
Advanced therapeutic for Parkinson's Disease
Amount: $3,100,838.00Parkinsonandapos;s Disease (PD) is a progressive neurodegenerative disorder that affects ≈1 million patient in the U.S. annually and 7 to 10 million people worldwide. PD is characterized by disorder ...
SBIRPhase II2019Department of Health and Human Services National Institutes of Health -
Advanced Prodrug Treatment for CML
Amount: $2,002,000.00Inhibikase Therapeutics is a clinical stagebio pharmaceutical company that has developed a novel prodrug formulation for the popular anticancer agent GleevecGleevectreatment is commonly accompanied by ...
SBIRPhase II2018Department of Health and Human Services National Institutes of Health -
Advanced PML antiviral
Amount: $2,000,000.00Inhibikase Therapeutics is a clinical stagebiopharmaceutical company that has developed a hosttargeted mechanism of action to treat AIDS related and drug induced progressive multifocal leukoencephalop ...
SBIRPhase II2017Department of Health and Human Services National Institutes of Health -
Prodrug treatment for CML
Amount: $284,778.00Inhibikase Therapeutics is a clinical stage bio pharmaceutical company that has developed a novel prodrug formulation for the popular anticancer agent Gleevec Gleevec treatment is commonly accompa ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
Advanced therapeutic for Parkinson's Disease
Amount: $3,108,583.00Parkinson s DiseasePDis a progressive neurodegenerative disorder that affectsmillion patient in the U Sannually andtomillion people worldwidePD is characterized by disorders of movementwhich are cause ...
SBIRPhase II2017Department of Health and Human Services National Institutes of Health -
Novel DFG out inhibitors of Abl-kinases to treat PML
Amount: $1,787,776.00DESCRIPTION provided by applicant Inhibikase Therapeutics is a clinical stage biopharmaceutical company that has developed a host targeted mechanism of action to treat AIDS related and drug induced pr ...
SBIRPhase II2016Department of Health and Human Services National Institutes of Health -
System for multidimensional analysis of growth and migration of neurons and neuro
Amount: $300,000.00DESCRIPTION (provided by applicant): Inhibikase Therapeutics is a clinical stage, biopharmaceutical company that has developed a host- targeted mechanism of action to treat AIDS-related and drug-induc ...
SBIRPhase I2013Department of Health and Human Services National Institutes of Health -
PML antiviral for AIDS
Amount: $265,846.00DESCRIPTION (provided by applicant): Inhibikase Therapeutics is an early stage biopharmaceutical company developing a novel strategy for treating infectious disease that occurs in AIDS patients. The ...
SBIRPhase I2009Department of Health and Human Services National Institutes of Health
